Harvard Business Review

AUGUST 3, 2012

They might make a targeted acquisition here or there, form an alliance now and again, or license in some specialized technology, but by and large they made their own drugs, supporting big, fully staffed research labs, which they would then market themselves.

Licensing 13

Licensing Depreciation Pharmaceuticals Budgeting 13

Strategy Driven

JANUARY 24, 2011

Execution Gap Maker #2: Nokia Nokia’s share of the worldwide market for mobile phones continued to slip in 2010. Why was this once-dominant player unable to execute and maintain its market position? So what happened? It appears Nokia was not able to coordinate decisions and activities across departments or levels of management.

Execution 67

Execution Company 360-Degree Feedback Cooper 67

Strategy Driven

MARCH 18, 2011

In The Essential Advantage : How to Win with a Capabilities-Driven Strategy , Booz & Company’s Paul Leinwand and Cesare Mainardi maintain that success in any market accrues to firms with a coherence premium – a tight match between their strategic direction and the capabilities that make them unique. Let’s go after it.”

Resources 52

Resources Industry System Strategy 52

Harvard Business Review

APRIL 16, 2014

That is perhaps the most frequent question I’ve received since 2011 when GlaxoSmithKline changed the link between the bonus pay of our pharmaceutical sales professionals in the United States and the numbers of prescription sold for a particular medicine. Critics may say it took a settlement with the U.S.

Incentives 12

Incentives Pharmaceuticals Health Care Metrics 12

Harvard Business Review

AUGUST 17, 2012

It has doubled its market cap in the five years and sales reached almost $1.5 What's more, these are markets that traditional developed market firms are increasingly targeting for their own growth goals. and other traditionally developed markets. and other traditionally developed markets.

Company 11

Company Pharmaceuticals Business Model Fixed Costs 11

Harvard Business Review

NOVEMBER 2, 2018

Competing for scarce labor in a tight market, they will have trouble continuing to shift medical bills onto employees as they have for several decades. To address these challenges, they will have to band together in purchasing coalitions that give them the local market power to force health systems to reform. Tim Robberts/Getty Images.

Health Care 8

Health Care Cost Insurance Price 8

Harvard Business Review

DECEMBER 12, 2012

Based on data covering the period from 2005 to 2011, it charts how globalization has evolved since the onset of the financial crisis at the global, regional, and national levels. Capital markets are fragmenting and while merchandise trade recovered strongly since 2009, the intensity of services trade has remained stagnant.

Report 15

Report Merchandising GDP Globalization 15

Harvard Business Review

NOVEMBER 8, 2017

With expanding middle classes demanding more-comprehensive care, governments of these emerging markets are under pressure to invest as chronic disease rates — particularly those related to Western lifestyles — dramatically increase and the average age of their once-young populations begins to rise. Insight Center.

Health Care 8

Health Care Tourism Pharmaceuticals Cost 8

Harvard Business Review

SEPTEMBER 11, 2014

That means new technologies and new competitors are hitting the market at an unprecedented rate. Finally, industries in the upper-right quadrant — such as software, pharmaceuticals, and medical equipment — face high uncertainty in both demand and technology. To illustrate this, consider that patent applications in the U.S.

Uncertainty 22

Uncertainty Industry Bottom-up Technology 22

Harvard Business Review

JANUARY 26, 2011

Companies included in the ETF include major airlines, pharmaceuticals, industrials, and technology. By the end of October in 2010, the market value of the 100 constituent stocks reached 582 billion RMB, accounting for 31% of the total market value of the Shanghai Stock Exchange's A shares. Stay tuned.

Long-term 14

Long-term Sample Pharmaceuticals Report 14

Harvard Business Review

MAY 10, 2013

As noted management expert Geoffrey Moore told me with respect to high-velocity competition, "I''m not sure you ever want to be in the public markets." Its RAZR thin phone was a huge success in the mid-2000''s, and the market raved. Take Motorola, for instance. Take Motorola, for instance.

Venture Capitalist 8

Venture Capitalist Restructuring Competitive Advantage Short-term 8

Harvard Business Review

MAY 25, 2017

The pipeline for new drugs is bursting, and new devices and tools in the rapidly emerging digital health space will come to market more quickly. Investors are already keenly focused on this area, with many startups competing for a slice of the market. A third growth area is in EHRs and digital health applications.

Health Care 8

Health Care Trends Venture Funding Technology 8

Harvard Business Review

MARCH 2, 2012

As global companies focus their strategies on developed and emerging markets, they require substantial cadres of leaders capable of operating effectively anywhere in the world. In 2011, 71% of HBS's new cases were written about foreign companies. Nestle, Unilever, and Novartis have several business units based in the U.S.

Competitive Advantage 13

Competitive Advantage Globalization Development Intellectual Capital 13

Harvard Business Review

NOVEMBER 20, 2015

He is poised to become the leader in this segment of a multi-billion dollar market. Compliance is crucial for pharmaceutical makers such as Abbott and Amgen – a “ Form 483 ” warning from an FDA inspector can shut down a drug facility in an instant and even land top executives in jail.

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

DECEMBER 21, 2015

Which brings us back to Pfizer, the pharmaceutical drug company that has provoked the new round of patriotic denunciations of corporate tax flight. Since 2011, Read’s first full year as CEO, Pfizer has expended $44.2 Pfizer’s CEO, Ian C. billion on buybacks and $31.2 Tammy Baldwin , Sen. Elizabeth Warren , Sen.

Hedge 8

Hedge Proposal Pharmaceuticals Price 8

Harvard Business Review

NOVEMBER 21, 2013

For many years, beginning in 1942, Premarin was the only hormone replacement therapy drug on the market derived from a natural source. Wyeth, a pharmaceutical acquired by Pfizer in 2009, was the sole supplier of Premarin. Why do some companies choose to patent their innovation while others choose to hide it? Such was not the case.

Intangible Assets 8

Intangible Assets Merchandising Innovation Pharmaceuticals 8

Harvard Business Review

FEBRUARY 24, 2015

The first category is exogenous factors over which the business has little control: the growth of the markets into which it sells; the competitive intensity and thus the average profitability of the industry in which it operates; or the fragmentation of its industry and thus the scope for a growth-by-acquisition approach.

Chemicals 8

Chemicals How To Reputation Kahneman 8

Harvard Business Review

JUNE 16, 2016

To understand the nature of the problem, let’s look at how penicillin was brought to market. The initial breakthrough came in 1987, but the first drug wasn’t approved until 2011. Profit-driven companies, on the other hand, feel so much pressure to go to market that they often pass on ideas with vast potential.

Technology 8

Technology Venture Capitalist Supply Chain Innovation 8

Harvard Business Review

SEPTEMBER 14, 2011

We recently visited the brand-new R&D lab of Dr Reddy's , one of India's leading pharmaceutical firms. In 2008, Dr Reddy's acquired Chirotech, Dow Chemical's R&D unit, for $32 million, and in April 2011 relocated it to a new 33,000 sq. This lab isn't located in Bangalore or Hyderabad (where Dr Reddy's is headquartered) but in.

Globalization 9

Globalization Innovation Decentralization Chemicals 9

Harvard Business Review

MAY 17, 2012

Most importantly, priced at approximately $200, the Embrace portable infant warmer costs merely 1 percent of what incubators in Western markets cost. In 2011, Embrace piloted the product in India, where 1.2 Embrace has already negotiated partnerships with multinational pharmaceutical and medical device companies such as GE Healthcare.

Incubator 11

Incubator Business Model Entrepreneur Cost 11

Harvard Business Review

DECEMBER 14, 2015

“There was this one instance where the market tanked and there was panic on the desk. Thanks to my meditation practice, I was able to keep my composure and propose solutions to reduce the impact of the market crash.” He claims meditation helped him keep fear and panic at bay, even under duress. ” You and Your Team.

CEO 8

CEO Emotional Intelligence Cooper Pharmaceuticals 8

Harvard Business Review

JUNE 21, 2017

We decided to create a direct-to-patient initiative using Collective Impact, a framework for tackling social issues first articulated , in 2011, by John Kania and Mark Kramer. Marketing executives from each organization committed to weekly calls and monthly face-to-face meetings that were led by the Accelerator.

Metrics 8

Metrics Learning-by-Doing Health Care Education 8

Harvard Business Review

JUNE 29, 2015

If you ask someone who works in finance (as I had to) about PE and innovation, he or she will likely tell you that PE sponsors aren’t looking for the next big thing—they’re looking for companies that are dominant in a market, aren’t risky, and have a predictable and steady stream of cash to pay back debt.

LBO 8

LBO Innovation Sample Short-term 8